Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Am J Hematol ; 62(1): 33-43, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10467274

RESUMO

The administration of retinoids has been demonstrated to be of potential utility in the therapy of a wide spectrum of neoplastic pathologies due to the ability to induce differentiation in a large variety of primary tumor cells as well as in vitro cultured cell lines. Moreover, a number of compounds, including hemin, cytosine arabinoside, and 5-azacytidine are able to induce erythroid differentiation of the erythroleukemic cell line K562. In this paper we determined whether a combined treatment of K562 cells with suboptimal concentrations of cytosine arabinoside and retinoids containing liposomes lead to a full expression of differentiated functions. Liposomes were prepared by reverse phase evaporation technique followed by extrusion through polycarbonate filters. Cell growth kinetics studies and intracellular detection of hemoglobin by benzidine staining were performed. The results obtained showed that the combined treatment with liposomes containing retinoids and sub-optimal concentration of ara-C is an effective strategy to induce K562 cell differentiation, minimizing at the same time toxic effects. Control experiments aimed to determine possible selection of subpopulations of K562 cells suggest that the observed results are not related to toxicity and/or potential selection of induced cells. In conclusion, liposomally delivered retinoids could be proposed for differentiation therapy as an effective strategy in the treatment and management of malignancy. In addition, the finding that liposomally delivered retinoids increase the capacity of cytosine arabinoside to induce erythroid differentiation, could be of interest in studies aimed at the development of treatment able to reactivate fetal globin genes in beta-thalassemia patients.


Assuntos
Citarabina/farmacologia , Células K562/efeitos dos fármacos , Tretinoína/farmacologia , Vitamina A/farmacologia , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Sinergismo Farmacológico , Técnica de Fratura por Congelamento , Hemoglobinas/análise , Humanos , Células K562/química , Lipossomos
2.
Eur J Haematol ; 61(5): 295-301, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-9855243

RESUMO

Human leukemia K562 cells can be induced to erythroid differentiation when treated with a variety of compounds, including hemin, cytosine arabinoside and 5-azacytidine. Following erythroid induction, K562 cells express at high level gamma-globin and accumulate both Hb Portland and Hb Gower 1. In this paper we determined whether a combination treatment of K562 cells with suboptimal concentrations of cytosine arabinoside and retinoids lead to full expression of differentiated functions. Cell growth kinetics studies, intracellular detection of hemoglobin by benzidine staining and hemoglobin analysis by cellulose acetate were performed. The results obtained show that (a) retinoic acid and retinol are not able to induce differentiation of K562 cells and (b) cytosine arabinoside induces differentiation only when used at 100-300 nmol/l concentrations. In addition, our data demonstrate that erythroid differentiation of K562 occurs when 40 micromol/l of retinoic acid or retinol are added together with 75 nmol/l cytosine arabinoside.


Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Citarabina/farmacologia , Eritropoese/efeitos dos fármacos , Células K562/efeitos dos fármacos , Células K562/patologia , Ceratolíticos/farmacologia , Tretinoína/farmacologia , Vitamina A/farmacologia , Antimetabólitos Antineoplásicos/uso terapêutico , Diferenciação Celular/efeitos dos fármacos , Citarabina/uso terapêutico , Sinergismo Farmacológico , Humanos , Leucemia/tratamento farmacológico , Leucemia/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...